[PDF] Top 20 White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing Remitting Multiple Sclerosis

... Patients receiving IFNb/GA were already receiving and con- tinuing IFNb/GA as their regular medical treatment. Eleven pa- tients were continuing IFN-b-1a/b (dose and route of administra- tion dependent on type), ... See full document

... of natalizumab on axonal function- ing in patients with RRMS was assessed by using MRSI because natalizumab has a substantial clinical ...with natalizumab showed an increase in tNAA, tCr, and Glu in ... See full document

... to treatment with alemtuzumab, the patient was treated with IFN, natalizumab and ...this first cycle of alemtu- zumab, the woman, during the stable phase of disease, was hospitalized for ... See full document

... the first 2 months of therapy, whereas relevant cytokines for MS such as IL-2, IL-7, or IL-1β have been found to be increased after one year of treatment, suggesting differ- ent immunological ... See full document

... the first clinical event (mean age, ...FSL FIRST, while whole-brain, GM, white matter, cortical, and lateral ventricle volumes were estimated by using SIENAX ... See full document

... MS treatment outcome, NEDA has increas- ingly been used as a treatment goal [23, ...initiating natalizumab treatment early in their disease course (< 3 years from diagnosis) attained ... See full document

... immunomodulatory treatment in clinical trials ...to changes with time than brain N-acetylaspartate, may be less relevant to understanding the progression of ... See full document

... inflammatory white matter lesions per se ...higher white and gray matter atrophy and higher lesion ...disability, white and gray matter atrophy is a risk factor to have fatigue ... See full document

... placebo, during year two after treatment initiation ...as first-line treatment for RRMS) the effect of alemtuzu- mab on BPF was compared to that of high-dose high- frequency sub-cutis ... See full document

... Abstract: Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy ... See full document

... as natalizumab and fingolimod which, being selective and not cytotoxic, are associated with reactivation of disease soon after ...cases, first-line treatment may lead to full efficacy at low ...the ... See full document

... torque during peripheral nerve stimulation in individuals with MS, as well as a positive correlation between fatigability and UMN dysfunction and metabolic changes during exercise, but not with ... See full document

... with relapsing-remitting multiple sclerosis treated with NTZ, 2 with leukemia, 2 treated with immunosuppressive therapies after liver or renal transplant, and 1 with neurosarcoidosis (8 women; ... See full document

... later treatment and would result in permanent ...effective treatment, one could use data from several studies that outline potential early prognostic indica- tors that might give us insight into an ... See full document

... among natalizumab-treated patients should be interpreted with caution, since the visual-analogue scale used to assess well-being has not been widely ...the natalizumab-treated pa- tients, the clinical ... See full document

... clinical as well as radiological endpoints. Twenty-seven patients in varying stages of disease were enrolled and assessed before and 18 months after a single pulse of alemtuzumab. The drug was found to be more effective ... See full document

... to natalizumab is a cost- effective option ...failed first-line therapy (IFNs, GA). To our knowledge, this is the first attempt of evaluating economic consequences of early escalation ...with ... See full document

... National Multiple Sclerosis Society, from posters and flyers distributed to neurology clinics in the Iowa City/Cedar Rapids, Iowa corridor area (to include the Iowa City Veterans Affairs Medical Center), ... See full document

... Multiple sclerosis (MS) is a neurodegenerative disorder that is characterized by motor dysfunction and disseminated axonal degeneration as well as inflammatory demyelina- tion in the central nervous ...of ... See full document

... While a range of targets were predicted by miRSystem [35], fold changes in differentially expressed miRNAs were only minor, reducing the likelihood that a single miRNA is affecting gene expression. Nonetheless, ... See full document